
Sent#, Event#, Subject, Event, Object, Site(s), Context, Sentence1, 1352, "WE", #<select 1352>, "DRUG", NIL, NIL, "We selected four drugs for our studies (Figures S1A–S1D);"
2, 1450, "DRUG", #<inhibit 1450>, "PROTEIN:V600EBRAF", NIL, NIL, "Sorafenib is a class II (inactive conformation binder) drug (Wan et al;; 2004) that inhibits V600EBRAF at 40 nM; CRAF at 13 nM; and several other kinases in the low nM range (Wilhelm et al;; 2004);"
2, 1449, "DRUG:sorafenib", #<is-bio-entity 1449>, "DRUG", NIL, NIL, "Sorafenib is a class II (inactive conformation binder) drug (Wan et al;; 2004) that inhibits V600EBRAF at 40 nM; CRAF at 13 nM; and several other kinases in the low nM range (Wilhelm et al;; 2004);"
3, 1448, NIL, #<is-bio-entity 1448>, "DRUG", NIL, NIL, "It is the least-selective drug that we used;"
3, 1449, "WE", #<use 1449>, NIL, NIL, NIL, "It is the least-selective drug that we used;"
4, 1439, "DRUG:plx4720", #<is-bio-entity 1439>, "INHIBITOR", NIL, NIL, "PLX4720 is a class I (active conformation binder) inhibitor that is highly selective and inhibits V600EBRAF at 13 nM (Tsai et al;; 2008);"
4, 1440, NIL, #<inhibit 1440>, "PROTEIN:V600EBRAF", NIL, NIL, "PLX4720 is a class I (active conformation binder) inhibitor that is highly selective and inhibits V600EBRAF at 13 nM (Tsai et al;; 2008);"
5, 1430, "DRUG:885-A", #<is-bio-entity 1430>, "ANALOG", NIL, NIL, "885-A (Figure S1C) is a close analog of the class I inhibitor SB590885 (King et al;; 2006) that is also highly selective for BRAF;"
6, 1412, NIL, #<inhibit 1412>, "PROTEIN:V600EBRAF", NIL, NIL, "It inhibits V600EBRAF at 2 nM (Figure S1E); is ineffective against a panel of 64 other protein kinases (Table S1); and preferentially blocks BRAF mutant cancer cell proliferation (Figure S1F);"
6, 1415, NIL, #<proliferate 1415>, "PROTEIN:BRaf", NIL, NIL, "It inhibits V600EBRAF at 2 nM (Figure S1E); is ineffective against a panel of 64 other protein kinases (Table S1); and preferentially blocks BRAF mutant cancer cell proliferation (Figure S1F);"
6, 1419, NIL, #<block 1419>, "EVENT-1415", NIL, NIL, "It inhibits V600EBRAF at 2 nM (Figure S1E); is ineffective against a panel of 64 other protein kinases (Table S1); and preferentially blocks BRAF mutant cancer cell proliferation (Figure S1F);"
7, 1409, "WE", #<use 1409>, "DRUG:pd184352", NIL, NIL, "Finally; we also used the potent and selective MEK inhibitor PD184352 (Sebolt-Leopold et al;; 1999);"
8, 1521, "DRUG", #<block 1521>, "EVENT-1526", NIL, NIL, "As expected; all four drugs blocked ERK activity in BRAF mutant A375 melanoma cells (Figure 1A; see Table S2);"
9, 1510, "DRUG", #<inhibit 1510>, "FAMILY:ERK", NIL, NIL, "Similarly; all four drugs inhibited ERK in SkMel24; SkMel28; D25; and WM266;4 cells; another four lines that express mutant BRAF (Figure S1G);"
9, 1512, "LINE", #<gene-transcript-express 1512>, NIL, NIL, NIL, "Similarly; all four drugs inhibited ERK in SkMel24; SkMel28; D25; and WM266;4 cells; another four lines that express mutant BRAF (Figure S1G);"
10, 1505, "WE", #<test 1505>, NIL, NIL, NIL, "We also tested the drugs in D04; MM415; MM485; and WM852 NRAS mutant cells (Table S2);"
11, 1497, "<collection DRUG:pd184352 DRUG:sorafenib>", #<inhibit 1497>, "FAMILY:ERK", NIL, NIL, "As expected; PD184352 and sorafenib inhibited ERK in all of these lines (Figure 1A);"
12, 1493, "<collection DRUG:plx4720 DRUG:885-A>", #<cause 1493>, "EVENT-1492", NIL, NIL, "Surprisingly; however; PLX4720 and 885-A caused an unexpected increase in ERK activity in the NRAS mutant cells (Figure 1A);"
13, 1482, NIL, #<bio-activate 1482>, "PATHWAY:MEK/ERK", NIL, NIL, "NRAS or CRAF depletion by RNA interference (RNAi) blocked MEK/ERK activation by PLX4720 and 885-A in NRAS mutant cells (Figure 1B and 1C) and we show that 885-A activated CRAF in these cells (Figure 1D);"
13, 1481, NIL, #<block 1481>, "EVENT-1482", NIL, NIL, "NRAS or CRAF depletion by RNA interference (RNAi) blocked MEK/ERK activation by PLX4720 and 885-A in NRAS mutant cells (Figure 1B and 1C) and we show that 885-A activated CRAF in these cells (Figure 1D);"
13, 1608, "<collection DRUG:plx4720 DRUG:885-A>", #<bio-activate 1608>, "PATHWAY:MEK/ERK", NIL, NIL, "NRAS or CRAF depletion by RNA interference (RNAi) blocked MEK/ERK activation by PLX4720 and 885-A in NRAS mutant cells (Figure 1B and 1C) and we show that 885-A activated CRAF in these cells (Figure 1D);"
13, 1607, "EVENT-1608", #<deplete 1607>, "<collection PROTEIN:NRas PROTEIN:CRaf>", NIL, NIL, "NRAS or CRAF depletion by RNA interference (RNAi) blocked MEK/ERK activation by PLX4720 and 885-A in NRAS mutant cells (Figure 1B and 1C) and we show that 885-A activated CRAF in these cells (Figure 1D);"
13, 1611, "WE", #<show 1611>, NIL, NIL, NIL, "NRAS or CRAF depletion by RNA interference (RNAi) blocked MEK/ERK activation by PLX4720 and 885-A in NRAS mutant cells (Figure 1B and 1C) and we show that 885-A activated CRAF in these cells (Figure 1D);"
13, 1609, "DRUG:885-A", #<bio-activate 1609>, "PROTEIN:CRaf", NIL, NIL, "NRAS or CRAF depletion by RNA interference (RNAi) blocked MEK/ERK activation by PLX4720 and 885-A in NRAS mutant cells (Figure 1B and 1C) and we show that 885-A activated CRAF in these cells (Figure 1D);"
14, 1602, "WE", #<report 1602>, NIL, NIL, NIL, "We previously reported that oncogenic RAS requires CRAF but not BRAF to activate MEK (Dumaz et al;; 2006) and consistent with this; BRAF is inactive in NRAS mutant cells (Figure 1E);"
14, 1600, "FAMILY:Ras", #<require 1600>, "PROTEIN:CRaf", NIL, NIL, "We previously reported that oncogenic RAS requires CRAF but not BRAF to activate MEK (Dumaz et al;; 2006) and consistent with this; BRAF is inactive in NRAS mutant cells (Figure 1E);"
14, 1599, NIL, #<bio-activate 1599>, "FAMILY:MEK", NIL, NIL, "We previously reported that oncogenic RAS requires CRAF but not BRAF to activate MEK (Dumaz et al;; 2006) and consistent with this; BRAF is inactive in NRAS mutant cells (Figure 1E);"
15, 1591, "ENTITY:data", #<present 1591>, NIL, NIL, NIL, "These data therefore present an intriguing paradox;"
16, 1585, NIL, #<bio-activate 1585>, "PATHWAY:MEK/ERK", NIL, NIL, "BRAF is not active and is not required for MEK/ERK activation in RAS mutant cells;"
16, 1581, NIL, #<require 1581>, "EVENT-1585", NIL, NIL, "BRAF is not active and is not required for MEK/ERK activation in RAS mutant cells;"
17, 1571, "INHIBITOR", #<bio-hyperactivate 1571>, "<collection PROTEIN:CRaf BIO-FAMILY:MEK>", NIL, NIL, "Nevertheless; BRAF inhibitors hyperactivate CRAF and MEK in these cells; so we studied the underlying mechanism(s);"
17, 1572, "EVENT-1573", #<underly 1572>, NIL, NIL, NIL, "Nevertheless; BRAF inhibitors hyperactivate CRAF and MEK in these cells; so we studied the underlying mechanism(s);"
17, 1574, "WE", #<study-bio-process 1574>, "EVENT-1573", NIL, NIL, "Nevertheless; BRAF inhibitors hyperactivate CRAF and MEK in these cells; so we studied the underlying mechanism(s);"
18, 1568, "WE", #<show 1568>, NIL, NIL, NIL, "In this study; we show that inhibition of BRAF by chemical or genetic means in the presence of oncogenic or growth-factor activated RAS induces BRAF binding to CRAF; leading to CRAF hyperactivation and consequently elevated MEK and ERK signaling;"
18, 1710, "EVENT-1566", #<inhibit 1710>, "PROTEIN:BRaf", NIL, NIL, "In this study; we show that inhibition of BRAF by chemical or genetic means in the presence of oncogenic or growth-factor activated RAS induces BRAF binding to CRAF; leading to CRAF hyperactivation and consequently elevated MEK and ERK signaling;"
18, 1721, "FAMILY:Ras", #<induce 1721>, NIL, NIL, NIL, "In this study; we show that inhibition of BRAF by chemical or genetic means in the presence of oncogenic or growth-factor activated RAS induces BRAF binding to CRAF; leading to CRAF hyperactivation and consequently elevated MEK and ERK signaling;"
18, 1712, "PROTEIN:BRaf", #<bio-bind 1712>, "PROTEIN:CRaf", NIL, NIL, "In this study; we show that inhibition of BRAF by chemical or genetic means in the presence of oncogenic or growth-factor activated RAS induces BRAF binding to CRAF; leading to CRAF hyperactivation and consequently elevated MEK and ERK signaling;"
18, 1718, NIL, #<bio-hyperactivate 1718>, "PROTEIN:CRaf", NIL, NIL, "In this study; we show that inhibition of BRAF by chemical or genetic means in the presence of oncogenic or growth-factor activated RAS induces BRAF binding to CRAF; leading to CRAF hyperactivation and consequently elevated MEK and ERK signaling;"
18, 1713, NIL, #<lead 1713>, "EVENT-1718", NIL, NIL, "In this study; we show that inhibition of BRAF by chemical or genetic means in the presence of oncogenic or growth-factor activated RAS induces BRAF binding to CRAF; leading to CRAF hyperactivation and consequently elevated MEK and ERK signaling;"
18, 1715, NIL, #<elevate 1715>, "EVENT-1716", NIL, NIL, "In this study; we show that inhibition of BRAF by chemical or genetic means in the presence of oncogenic or growth-factor activated RAS induces BRAF binding to CRAF; leading to CRAF hyperactivation and consequently elevated MEK and ERK signaling;"
19, 1707, NIL, #<bio-activate 1707>, "FAMILY:Raf", NIL, NIL, "The mechanism we describe is another paradigm of RAF activation downstream of RAS and based on our findings; we propose the following mechanism by which this occurs;"
19, 1703, "WE", #<propose 1703>, "EVENT-1702", NIL, NIL, "The mechanism we describe is another paradigm of RAF activation downstream of RAS and based on our findings; we propose the following mechanism by which this occurs;"
20, 1694, "WE", #<posit 1694>, NIL, NIL, NIL, "We posit that in RAS mutant cells; BRAF maintains itself in an inactive conformation through its own kinase activity; either through auto-phosphorylation; or by phosphorylating a partner protein that then keeps it inactive (Figure 7A);"
20, 1691, "PROTEIN:BRaf", #<maintain 1691>, NIL, NIL, NIL, "We posit that in RAS mutant cells; BRAF maintains itself in an inactive conformation through its own kinase activity; either through auto-phosphorylation; or by phosphorylating a partner protein that then keeps it inactive (Figure 7A);"
20, 1696, NIL, #<phosphorylate 1696>, "EVENT-NIL", NIL, NIL, "We posit that in RAS mutant cells; BRAF maintains itself in an inactive conformation through its own kinase activity; either through auto-phosphorylation; or by phosphorylating a partner protein that then keeps it inactive (Figure 7A);"
20, 1687, NIL, #<phosphorylate 1687>, "PROTEIN", NIL, NIL, "We posit that in RAS mutant cells; BRAF maintains itself in an inactive conformation through its own kinase activity; either through auto-phosphorylation; or by phosphorylating a partner protein that then keeps it inactive (Figure 7A);"
21, 1680, "WE", #<use 1680>, NIL, NIL, NIL, "We are currently using mass-spectrometry and mutagenic approaches to elucidate the underlying mechanism;"
21, 1674, "EVENT-1675", #<underly 1674>, NIL, NIL, NIL, "We are currently using mass-spectrometry and mutagenic approaches to elucidate the underlying mechanism;"
21, 1676, NIL, #<elucidate 1676>, "EVENT-1675", NIL, NIL, "We are currently using mass-spectrometry and mutagenic approaches to elucidate the underlying mechanism;"
22, 1868, "WE", #<propose 1868>, NIL, NIL, NIL, "We propose that when BRAF is  inhibited; it escapes this auto-inhibited fate and is recruited to the plasma membrane by RAS; where it forms a stable complex with CRAF;"
22, 1867, NIL, #<inhibit 1867>, "PROTEIN:BRaf", NIL, NIL, "We propose that when BRAF is  inhibited; it escapes this auto-inhibited fate and is recruited to the plasma membrane by RAS; where it forms a stable complex with CRAF;"
22, 1864, NIL, #<inhibit 1864>, "FATE", NIL, NIL, "We propose that when BRAF is  inhibited; it escapes this auto-inhibited fate and is recruited to the plasma membrane by RAS; where it forms a stable complex with CRAF;"
22, 1858, "FAMILY:Ras", #<recruit 1858>, NIL, NIL, NIL, "We propose that when BRAF is  inhibited; it escapes this auto-inhibited fate and is recruited to the plasma membrane by RAS; where it forms a stable complex with CRAF;"
22, 1861, NIL, #<form 1861>, "COMPLEX", NIL, NIL, "We propose that when BRAF is  inhibited; it escapes this auto-inhibited fate and is recruited to the plasma membrane by RAS; where it forms a stable complex with CRAF;"
23, 1855, "WE", #<posit 1855>, NIL, NIL, NIL, "Critically; we posit that because it is inhibited; BRAF does not directly phosphorylate MEK; but rather it acts as a scaffold whose function is to enhance CRAF activation; thereby allowing CRAF to hyperactivate the pathway (Figure 7B);"
23, 1851, "PROTEIN:BRaf", #<phosphorylate 1851>, "FAMILY:MEK", NIL, NIL, "Critically; we posit that because it is inhibited; BRAF does not directly phosphorylate MEK; but rather it acts as a scaffold whose function is to enhance CRAF activation; thereby allowing CRAF to hyperactivate the pathway (Figure 7B);"
23, 1842, NIL, #<bio-activate 1842>, "PROTEIN:CRaf", NIL, NIL, "Critically; we posit that because it is inhibited; BRAF does not directly phosphorylate MEK; but rather it acts as a scaffold whose function is to enhance CRAF activation; thereby allowing CRAF to hyperactivate the pathway (Figure 7B);"
23, 1843, NIL, #<bio-enhance 1843>, "EVENT-1842", NIL, NIL, "Critically; we posit that because it is inhibited; BRAF does not directly phosphorylate MEK; but rather it acts as a scaffold whose function is to enhance CRAF activation; thereby allowing CRAF to hyperactivate the pathway (Figure 7B);"
23, 1840, "PROTEIN:CRaf", #<allow 1840>, NIL, NIL, NIL, "Critically; we posit that because it is inhibited; BRAF does not directly phosphorylate MEK; but rather it acts as a scaffold whose function is to enhance CRAF activation; thereby allowing CRAF to hyperactivate the pathway (Figure 7B);"
24, 1935, NIL, #<bio-bind 1935>, "FAMILY:Ras", NIL, NIL, "We do not know the stoichiometry of the components in these complexes; but since BRAF and CRAF must both bind to RAS for complex formation; it seems likely that at least two RAS proteins are needed to stimulate formation of the complex (Figure 7B);"
24, 1826, NIL, #<form 1826>, "EVENT-NIL", NIL, NIL, "We do not know the stoichiometry of the components in these complexes; but since BRAF and CRAF must both bind to RAS for complex formation; it seems likely that at least two RAS proteins are needed to stimulate formation of the complex (Figure 7B);"
24, 1822, "PROTEIN", #<need 1822>, NIL, NIL, NIL, "We do not know the stoichiometry of the components in these complexes; but since BRAF and CRAF must both bind to RAS for complex formation; it seems likely that at least two RAS proteins are needed to stimulate formation of the complex (Figure 7B);"
24, 1942, NIL, #<form 1942>, "COMPLEX", NIL, NIL, "We do not know the stoichiometry of the components in these complexes; but since BRAF and CRAF must both bind to RAS for complex formation; it seems likely that at least two RAS proteins are needed to stimulate formation of the complex (Figure 7B);"
24, 1821, NIL, #<stimulate 1821>, "EVENT-1942", NIL, NIL, "We do not know the stoichiometry of the components in these complexes; but since BRAF and CRAF must both bind to RAS for complex formation; it seems likely that at least two RAS proteins are needed to stimulate formation of the complex (Figure 7B);"
25, 1932, "WE", #<test 1932>, NIL, NIL, NIL, " Next; we tested whether overexpression of these genes was sufficient to activate the MAPK pathway;"
25, 1929, NIL, #<bio-activate 1929>, "FAMILY:MAPK", NIL, NIL, " Next; we tested whether overexpression of these genes was sufficient to activate the MAPK pathway;"
26, 1925, NIL, #<gene-transcript-express 1925>, "PROTEIN:cot", NIL, NIL, "At baseline; COT expression increased ERK phosphorylation in a manner comparable to MEK1DD; consistent with MAP kinase pathway activation (Fig; 2a and Supplementary Fig; 6);"
26, 1924, "EVENT-1925", #<increase 1924>, NIL, NIL, NIL, "At baseline; COT expression increased ERK phosphorylation in a manner comparable to MEK1DD; consistent with MAP kinase pathway activation (Fig; 2a and Supplementary Fig; 6);"
26, 1923, NIL, #<phosphorylate 1923>, "FAMILY:ERK", NIL, NIL, "At baseline; COT expression increased ERK phosphorylation in a manner comparable to MEK1DD; consistent with MAP kinase pathway activation (Fig; 2a and Supplementary Fig; 6);"
26, 1917, NIL, #<bio-activate 1917>, "PROTEIN:MAP", NIL, NIL, "At baseline; COT expression increased ERK phosphorylation in a manner comparable to MEK1DD; consistent with MAP kinase pathway activation (Fig; 2a and Supplementary Fig; 6);"
27, 1906, NIL, #<phosphorylate 1906>, "<collection BIO-FAMILY:ERK BIO-FAMILY:MEK>", NIL, NIL, "Overexpression of wild-type COT or C-RAF resulted in constitutive phosphorylation of ERK and MEK in the presence of PLX4720; whereas kinase-dead derivatives had no effect (Fig; 2a; Supplementary Fig; 7);"
27, 1904, NIL, #<result 1904>, "EVENT-1906", NIL, NIL, "Overexpression of wild-type COT or C-RAF resulted in constitutive phosphorylation of ERK and MEK in the presence of PLX4720; whereas kinase-dead derivatives had no effect (Fig; 2a; Supplementary Fig; 7);"
28, 1900, "WE", #<hypothesize 1900>, NIL, NIL, NIL, "Based on these results; we hypothesized that COT and C-RAF drive resistance to RAF inhibition predominantly through re-activation of MAPK signaling;"
28, 1897, NIL, #<inhibit 1897>, "FAMILY:Raf", NIL, NIL, "Based on these results; we hypothesized that COT and C-RAF drive resistance to RAF inhibition predominantly through re-activation of MAPK signaling;"
28, 2109, NIL, #<resist 2109>, "EVENT-1897", NIL, NIL, "Based on these results; we hypothesized that COT and C-RAF drive resistance to RAF inhibition predominantly through re-activation of MAPK signaling;"
28, 2110, NIL, #<bio-activate 2110>, "EVENT-2111", NIL, NIL, "Based on these results; we hypothesized that COT and C-RAF drive resistance to RAF inhibition predominantly through re-activation of MAPK signaling;"
29, 2095, NIL, #<phosphorylate 2095>, "ENTITY:ERK/MEK", NIL, NIL, "Notably; of the nine candidate ORFs from our initial screen; a subset (3) did not show persistent ERK/MEK phosphorylation following RAF inhibition; suggesting MAPK pathway-independent alteration of drug sensitivity (Supplementary Fig; 8);"
29, 2093, NIL, #<inhibit 2093>, "FAMILY:Raf", NIL, NIL, "Notably; of the nine candidate ORFs from our initial screen; a subset (3) did not show persistent ERK/MEK phosphorylation following RAF inhibition; suggesting MAPK pathway-independent alteration of drug sensitivity (Supplementary Fig; 8);"
29, 2099, NIL, #<show 2099>, "EVENT-2093", NIL, NIL, "Notably; of the nine candidate ORFs from our initial screen; a subset (3) did not show persistent ERK/MEK phosphorylation following RAF inhibition; suggesting MAPK pathway-independent alteration of drug sensitivity (Supplementary Fig; 8);"
29, 2089, NIL, #<alter 2089>, "FAMILY:MAPK", NIL, NIL, "Notably; of the nine candidate ORFs from our initial screen; a subset (3) did not show persistent ERK/MEK phosphorylation following RAF inhibition; suggesting MAPK pathway-independent alteration of drug sensitivity (Supplementary Fig; 8);"
29, 2088, "EVENT-2089", #<suggest 2088>, NIL, NIL, NIL, "Notably; of the nine candidate ORFs from our initial screen; a subset (3) did not show persistent ERK/MEK phosphorylation following RAF inhibition; suggesting MAPK pathway-independent alteration of drug sensitivity (Supplementary Fig; 8);"
29, 2086, NIL, #<alter 2086>, "SENSITIVITY", NIL, NIL, "Notably; of the nine candidate ORFs from our initial screen; a subset (3) did not show persistent ERK/MEK phosphorylation following RAF inhibition; suggesting MAPK pathway-independent alteration of drug sensitivity (Supplementary Fig; 8);"
32, 2079, NIL, #<bio-activate collection 2079>, "PROTEIN:CRaf", NIL, NIL, "Several groups have shown that C-RAF activation and heterodimerization with B-RAF constitute critical components of the cellular response to B-RAF inhibition;"
32, 2075, NIL, #<inhibit 2075>, "PROTEIN:BRaf", NIL, NIL, "Several groups have shown that C-RAF activation and heterodimerization with B-RAF constitute critical components of the cellular response to B-RAF inhibition;"
32, 2074, "EVENT-2075", #<response 2074>, NIL, NIL, NIL, "Several groups have shown that C-RAF activation and heterodimerization with B-RAF constitute critical components of the cellular response to B-RAF inhibition;"
34, 2217, NIL, #<phosphorylate 2217>, "PROTEIN:CRaf", NIL, NIL, "However; endogenous C-RAF phosphorylation at S338; an event required for C-RAF activation; remained low (Supplementary Fig; 9);"
34, 2219, NIL, #<bio-activate 2219>, "PROTEIN:CRaf", NIL, NIL, "However; endogenous C-RAF phosphorylation at S338; an event required for C-RAF activation; remained low (Supplementary Fig; 9);"
34, 2218, NIL, #<require 2218>, "EVENT-2219", NIL, NIL, "However; endogenous C-RAF phosphorylation at S338; an event required for C-RAF activation; remained low (Supplementary Fig; 9);"
35, 2210, NIL, #<gene-transcript-express 2210>, "PROTEIN:CRaf", NIL, NIL, "In contrast; ectopically expressed C-RAF was phosphorylated on S338 (Supplementary Fig; 9) and its PLX4720 resistance phenotype was associated with sustained MEK/ERK activation (Fig; 2a; Supplementary Fig; 9);"
35, 2200, NIL, #<phosphorylate 2200>, "PROTEIN:CRaf", NIL, NIL, "In contrast; ectopically expressed C-RAF was phosphorylated on S338 (Supplementary Fig; 9) and its PLX4720 resistance phenotype was associated with sustained MEK/ERK activation (Fig; 2a; Supplementary Fig; 9);"
35, 2201, NIL, #<sustain 2201>, "EVENT-2202", NIL, NIL, "In contrast; ectopically expressed C-RAF was phosphorylated on S338 (Supplementary Fig; 9) and its PLX4720 resistance phenotype was associated with sustained MEK/ERK activation (Fig; 2a; Supplementary Fig; 9);"
35, 2202, NIL, #<bio-activate 2202>, "PATHWAY:MEK/ERK", NIL, NIL, "In contrast; ectopically expressed C-RAF was phosphorylated on S338 (Supplementary Fig; 9) and its PLX4720 resistance phenotype was associated with sustained MEK/ERK activation (Fig; 2a; Supplementary Fig; 9);"
36, 2186, NIL, #<resist 2186>, "DRUG:plx4720", NIL, NIL, "Moreover; ectopic expression of a high-activity C-RAF truncation mutant (C-RAF W22) was more effective than wild-type C-RAF in mediating PLX4720 resistance and ERK activation (Supplementary Fig; 10); further indicating that elevated C-RAF activity may direct resistance to this agent;"
36, 2187, NIL, #<mediate 2187>, "EVENT-2186", NIL, NIL, "Moreover; ectopic expression of a high-activity C-RAF truncation mutant (C-RAF W22) was more effective than wild-type C-RAF in mediating PLX4720 resistance and ERK activation (Supplementary Fig; 10); further indicating that elevated C-RAF activity may direct resistance to this agent;"
36, 2185, NIL, #<bio-activate 2185>, "FAMILY:ERK", NIL, NIL, "Moreover; ectopic expression of a high-activity C-RAF truncation mutant (C-RAF W22) was more effective than wild-type C-RAF in mediating PLX4720 resistance and ERK activation (Supplementary Fig; 10); further indicating that elevated C-RAF activity may direct resistance to this agent;"
36, 2182, NIL, #<elevate 2182>, "EVENT-2183", NIL, NIL, "Moreover; ectopic expression of a high-activity C-RAF truncation mutant (C-RAF W22) was more effective than wild-type C-RAF in mediating PLX4720 resistance and ERK activation (Supplementary Fig; 10); further indicating that elevated C-RAF activity may direct resistance to this agent;"
36, 2178, NIL, #<resist 2178>, "AGENT", NIL, NIL, "Moreover; ectopic expression of a high-activity C-RAF truncation mutant (C-RAF W22) was more effective than wild-type C-RAF in mediating PLX4720 resistance and ERK activation (Supplementary Fig; 10); further indicating that elevated C-RAF activity may direct resistance to this agent;"
37, 2298, NIL, #<resist 2298>, "DRUG:plx4720", NIL, NIL, "Consistent with this model; oncogenic alleles of NRAS and KRAS conferred PLX4720 resistance in A375 cells (Fig; 2b) and yielded sustained C-RAF(S338) and ERK phosphorylation in the context of drug treatment (Fig; 2c);"
37, 2299, "ALLELE", #<confer 2299>, "EVENT-2298", NIL, NIL, "Consistent with this model; oncogenic alleles of NRAS and KRAS conferred PLX4720 resistance in A375 cells (Fig; 2b) and yielded sustained C-RAF(S338) and ERK phosphorylation in the context of drug treatment (Fig; 2c);"
42, 2262, NIL, #<gene-transcript-express 2262>, "PROTEIN:cot", NIL, NIL, "Ectopic COT expression in A375 and SKMEL28 cells also conferred decreased sensitivity to the MEK inhibitors CI-1040 and AZD6244; suggesting that COT expression alone was sufficient to induce this phenotype (Fig; 4c; 4d; Supplementary Fig; 17);"
42, 2258, NIL, #<confer 2258>, "SENSITIVITY", NIL, NIL, "Ectopic COT expression in A375 and SKMEL28 cells also conferred decreased sensitivity to the MEK inhibitors CI-1040 and AZD6244; suggesting that COT expression alone was sufficient to induce this phenotype (Fig; 4c; 4d; Supplementary Fig; 17);"
42, 2260, NIL, #<decrease 2260>, "SENSITIVITY", NIL, NIL, "Ectopic COT expression in A375 and SKMEL28 cells also conferred decreased sensitivity to the MEK inhibitors CI-1040 and AZD6244; suggesting that COT expression alone was sufficient to induce this phenotype (Fig; 4c; 4d; Supplementary Fig; 17);"
42, 2252, NIL, #<gene-transcript-express 2252>, "PROTEIN:cot", NIL, NIL, "Ectopic COT expression in A375 and SKMEL28 cells also conferred decreased sensitivity to the MEK inhibitors CI-1040 and AZD6244; suggesting that COT expression alone was sufficient to induce this phenotype (Fig; 4c; 4d; Supplementary Fig; 17);"
43, 2388, NIL, #<phosphorylate 2388>, "FAMILY:ERK", NIL, NIL, "Similar to results observed with pharmacological MEK inhibitors; MEK1/2 knockdown only modestly suppressed COT–mediated ERK phosphorylation in A375 cells (Supplementary Fig; 18);"
43, 2387, "PROTEIN:cot", #<mediate 2387>, "EVENT-2388", NIL, NIL, "Similar to results observed with pharmacological MEK inhibitors; MEK1/2 knockdown only modestly suppressed COT–mediated ERK phosphorylation in A375 cells (Supplementary Fig; 18);"
43, 2385, NIL, #<suppress 2385>, "EVENT-2386", NIL, NIL, "Similar to results observed with pharmacological MEK inhibitors; MEK1/2 knockdown only modestly suppressed COT–mediated ERK phosphorylation in A375 cells (Supplementary Fig; 18);"
43, 2386, NIL, #<phosphorylate 2386>, "FAMILY:ERK", NIL, NIL, "Similar to results observed with pharmacological MEK inhibitors; MEK1/2 knockdown only modestly suppressed COT–mediated ERK phosphorylation in A375 cells (Supplementary Fig; 18);"
44, 2374, "ENTITY:observations24,", #<raise 2374>, NIL, NIL, NIL, "In accordance with prior observations24; these data raised the possibility that COT may activate ERK through MEK-independent and MEK-dependent mechanisms;"
44, 2372, "PROTEIN:cot", #<bio-activate 2372>, "FAMILY:ERK", NIL, NIL, "In accordance with prior observations24; these data raised the possibility that COT may activate ERK through MEK-independent and MEK-dependent mechanisms;"
45, 2371, NIL, #<test 2371>, "EVENT-2368", NIL, NIL, "To test this hypothesis directly; we performed an in vitro kinase assay using recombinant COT and ERK1;"
45, 2366, "WE", #<perform 2366>, "EVENT-2364", NIL, NIL, "To test this hypothesis directly; we performed an in vitro kinase assay using recombinant COT and ERK1;"
45, 2363, NIL, #<use 2363>, "<collection PROTEIN:cot PROTEIN:ERK1>", NIL, NIL, "To test this hypothesis directly; we performed an in vitro kinase assay using recombinant COT and ERK1;"
46, 2481, NIL, #<phosphorylate 2481>, "PROTEIN:ERK1", NIL, NIL, "Indeed; recombinant COT induced pThr202/Tyr204 phosphorylation of ERK1 in vitro (Supplementary Fig;  18) suggesting that in certain contexts; COT expression may potentiate ERK activation in a MEK-independent manner;"
46, 2356, "PROTEIN:cot", #<induce 2356>, "EVENT-2481", NIL, NIL, "Indeed; recombinant COT induced pThr202/Tyr204 phosphorylation of ERK1 in vitro (Supplementary Fig;  18) suggesting that in certain contexts; COT expression may potentiate ERK activation in a MEK-independent manner;"
46, 2483, NIL, #<bio-activate 2483>, "FAMILY:ERK", NIL, NIL, "Indeed; recombinant COT induced pThr202/Tyr204 phosphorylation of ERK1 in vitro (Supplementary Fig;  18) suggesting that in certain contexts; COT expression may potentiate ERK activation in a MEK-independent manner;"
46, 2353, NIL, #<gene-transcript-express 2353>, "PROTEIN:cot", NIL, NIL, "Indeed; recombinant COT induced pThr202/Tyr204 phosphorylation of ERK1 in vitro (Supplementary Fig;  18) suggesting that in certain contexts; COT expression may potentiate ERK activation in a MEK-independent manner;"
46, 2352, "EVENT-2353", #<potentiate 2352>, "EVENT-2483", NIL, NIL, "Indeed; recombinant COT induced pThr202/Tyr204 phosphorylation of ERK1 in vitro (Supplementary Fig;  18) suggesting that in certain contexts; COT expression may potentiate ERK activation in a MEK-independent manner;"
49, 2470, NIL, #<study-bio-process 2470>, "ENTITY:Pre-clinical", NIL, NIL, "Pre-clinical studies have demonstrated that the B-RAFV600E mutation predicts a dependency on the mitogen activated protein kinase (MAPK) signaling cascade in melanoma [1–5] —an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials 6–8;"
49, 2465, NIL, #<mutate 2465>, "PROTEIN:V600EBRAF", NIL, NIL, "Pre-clinical studies have demonstrated that the B-RAFV600E mutation predicts a dependency on the mitogen activated protein kinase (MAPK) signaling cascade in melanoma [1–5] —an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials 6–8;"
49, 2449, NIL, #<predict 2449>, "EVENT-2450", NIL, NIL, "Pre-clinical studies have demonstrated that the B-RAFV600E mutation predicts a dependency on the mitogen activated protein kinase (MAPK) signaling cascade in melanoma [1–5] —an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials 6–8;"
49, 2458, NIL, #<observe 2458>, "ENTITY:—an", NIL, NIL, "Pre-clinical studies have demonstrated that the B-RAFV600E mutation predicts a dependency on the mitogen activated protein kinase (MAPK) signaling cascade in melanoma [1–5] —an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials 6–8;"
49, 2457, NIL, #<validate 2457>, "EVENT-2458", NIL, NIL, "Pre-clinical studies have demonstrated that the B-RAFV600E mutation predicts a dependency on the mitogen activated protein kinase (MAPK) signaling cascade in melanoma [1–5] —an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials 6–8;"
50, 2446, NIL, #<target 2446>, "THERAPEUTICS", NIL, NIL, "However; clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance [9–11];"
51, 2604, NIL, #<identify 2604>, "EVENT-2439", NIL, NIL, "Identification of resistance mechanisms in a manner that elucidates alternative ‘druggable’ targets may inform effective long-term treatment strategies [12];"
51, 2437, "EVENT-2438", #<elucidate 2437>, "EVENT-2605", NIL, NIL, "Identification of resistance mechanisms in a manner that elucidates alternative ‘druggable’ targets may inform effective long-term treatment strategies [12];"
52, 2592, NIL, #<resist 2592>, "INHIBITOR", NIL, NIL, "Here; we expressed ~600 kinase and kinase-related open reading frames (ORFs) in parallel to functionally interrogate resistance to a selective RAF kinase inhibitor;"
52, 2597, NIL, #<interrogate 2597>, "EVENT-2592", NIL, NIL, "Here; we expressed ~600 kinase and kinase-related open reading frames (ORFs) in parallel to functionally interrogate resistance to a selective RAF kinase inhibitor;"
53, 2591, "WE", #<identify 2591>, NIL, NIL, NIL, "We identified MAP3K8 (COT/TPL2) as a MAPK pathway agonist that drives resistance to RAF inhibition in BRAFV600E cell lines;"
53, 2586, NIL, #<inhibit 2586>, "FAMILY:Raf", NIL, NIL, "We identified MAP3K8 (COT/TPL2) as a MAPK pathway agonist that drives resistance to RAF inhibition in BRAFV600E cell lines;"
53, 2584, NIL, #<resist 2584>, "EVENT-2586", NIL, NIL, "We identified MAP3K8 (COT/TPL2) as a MAPK pathway agonist that drives resistance to RAF inhibition in BRAFV600E cell lines;"
54, 2577, "EVENT-2579", #<require 2577>, "EVENT-2574", NIL, NIL, "COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signaling;"
54, 2581, "PROTEIN:cot", #<bio-activate 2581>, "FAMILY:ERK", NIL, NIL, "COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signaling;"
55, 2570, NIL, #<gene-transcript-express 2570>, "PROTEIN:cot", NIL, NIL, "Moreover; COT expression is associated with de novo resistance in BRAFV600E cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibition;"
55, 2564, NIL, #<acquire 2564>, "EVENT-2565", NIL, NIL, "Moreover; COT expression is associated with de novo resistance in BRAFV600E cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibition;"
55, 2696, NIL, #<inhibit 2696>, "<collection BIO-FAMILY:MEK BIO-FAMILY:Raf>", NIL, NIL, "Moreover; COT expression is associated with de novo resistance in BRAFV600E cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibition;"
56, 2681, NIL, #<bio-activate 2681>, "FAMILY:MAPK", NIL, NIL, "We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting;"
56, 2683, NIL, #<reduce 2683>, "EVENT-2681", NIL, NIL, "We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting;"
57, 2665, NIL, #<articulate 2665>, "EVENT-2664", NIL, NIL, "Together; these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies;"
57, 2661, NIL, #<inform 2661>, "EVENT-2658", NIL, NIL, "Together; these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies;"
